Pharmaceutical

SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.

Feb 20, 2024 - 18:00
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

RioDerm-001 by Rion for Diabetic Foot Ulcers: Likelihood of Approval

Next Article

Denali-Sanofi’s ALS Candidate Falls Short in Mid-Stage Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Listen: How two abortion providers grapple with their post-Roe reality

Opinion: Listen: How two abortion providers grapple wit...

Oct 4, 2023

Banning WuXi is more complicated than it might sound

Banning WuXi is more complicated than it might sound

Mar 8, 2024

With latest tranche, U.K. Biobank has genome sequences from 500,000 people available for research

With latest tranche, U.K. Biobank has genome sequences ...

Nov 29, 2023